Why it was recalled
Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
Product description
Everolimus tablets 2.5 mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-119-91
Lot numbers, UPCs & expiration codes
Lot #: 550172201, Exp. Date JAN-26; 550184801, Exp. Date MAR-26; 550204001, Exp. Date JUL-26
Where it was sold
Nationwide within the United States
What to do if you have this product
- Compare the lot number and expiration date on your package with the codes above.
- Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
- If you have symptoms you think are related, contact your doctor. In an emergency call 911.
- Report side effects to FDA MedWatch at 1-800-FDA-1088.
Recall details
- Recall number
- D-0142-2026
- Classification
- Class III
- Status
- Ongoing
- Recall initiated
- Oct 10, 2025
- FDA report date
- Nov 5, 2025
- Quantity
- 2,035 cartons
- Recall type
- Voluntary: Firm initiated
- Recalling firm
- Endo USA, Inc.
Original FDA data
Every field from FDA enforcement report D-0142-2026, exactly as published.
Show all FDA fields
- City
- Malvern
- State
- PA
- Status
- Ongoing
- Country
- United States
- Event ID
- 97866
- Address
- 9 Great Valley Pkwy
- Code information
- Lot #: 550172201, Exp. Date JAN-26; 550184801, Exp. Date MAR-26; 550204001, Exp. Date JUL-26
- Postal code
- 19355-1304
- Report date
- Nov 5, 2025
- Product type
- Drugs
- Recall number
- D-0142-2026
- Classification
- Class III
- Recalling firm
- Endo USA, Inc.
- Product quantity
- 2,035 cartons
- Reason for recall
- Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.
- Voluntary / mandated
- Voluntary: Firm initiated
- Product description
- Everolimus tablets 2.5 mg, 28 tablets (each carton contains 4 blister strips with 7 tablets each), Rx only, Manufactured by: Par Pharmaceutical Chestnut Ridge, NY 10977 NDC# 49884-119-91
- Distribution pattern
- Nationwide within the United States
- Recall initiation date
- Oct 10, 2025
- Initial firm notification
- Letter
- Center classification date
- Oct 29, 2025